Skye Bioscience Inc (SKYE)

[Triple9]

"COSTA MESA, CA / ACCESSWIRE / February 13, 2017 / NEMUS Bioscience, Inc. (NMUS) announced that the company and its research and development partner, the University of Mississippi School of Pharmacy (UM), have conducted in vitro and in vivo bio-distribution and anti-addictive studies of NB2111, a unique analogue of cannabidiol (CBD). In the studies, NB2111 exhibited molecular stability in both gastric and intestinal pH modeling and did not convert to tetrahydrocannabinol (THC). We believe this is an important advantage over plant-derived CBD, which in these studies, partially converted to THC, the cannabinoid with psychoactive properties. Additionally, NB2111 exhibited an ability to penetrate all major organ systems, including the brain. Of note, the molecule showed a predilection for liver tissues that we believe might be exploited for the treatment of liver diseases responsive to cannabinoids. Lastly, NB2111 showed a statistically significant ability to mitigate opioid addiction in a validated animal model of addiction versus plant-derived CBD. This data complements the company's previously reported analgesic data related to NB2111 providing analgesia comparable to morphine."

http://finance.yahoo.com/news/nemus-bioscience-reports-favorable-bio-133000374.html

Great news! Doctors would certainly prescribe a med that had no psychoactive properties, over one that did, given a choice.

From what I've read, cannabinoids get converted by the liver, so for certain types of treatments it's desirable to go right to the bloodstream. Sounds like NB2111 is more stable than natural CBD in the liver, which could lead to novel liver treatments.

There is a huge need for non-addictive painkillers in the World. Very encouraging news.